Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 79,305 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: HSV Infection
Interventions: Pritelivir, Investigator's choice; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 16 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: Deoxycholic Acid, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more

Conditions: KCNT1-Related Epilepsy
Interventions: ABS-1230, Placebo; Drug
Lead sponsor: Actio Biosciences, Inc.; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Hackensack, New Jersey • Rochester, New York

Conditions: Dry Mouth
Interventions: Pilocarpine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Morbid Obesity
Interventions: Survey; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myelodysplastic Syndrome
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Multiple Myeloma
Interventions: GPT-QPL; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Substance Use Disorders, Parent-Child Relations, Parent Child Abuse
Interventions: MIO-CPP; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV-1-infection
Interventions: Albuvirtide, 3BNC117, Baseline ART; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Placebo, GM-CSF; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: AMG 160; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Catheter-Related Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Sarcoma, Dedifferentiated Liposarcoma
Interventions: Abemaciclib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Mold Infections
Interventions: Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more

Conditions: HIV
Interventions: Evolution: Young Women Taking Charge and Growing Stronger; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Tampa, Florida • Chicago, Illinois • Baltimore, Maryland

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: 2 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Plaque Psoriasis
Interventions: DFD01 Spray; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Encino, California • Irvine, California • San Diego, California + 5 more

Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions: Ibrutinib, Nivolumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: RO6895882; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Racial/Ethnic Minorities on Dialysis
Interventions: Active Comparator: peer navigator, Placebo Comparator: Control Arm (standard of care); Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Adjustable Gastric Band Survey Study

Three Dosing Schedules of Oral Rigosertib in MDS Patients

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

MIO-CPP to Improve the Well-being, Permanency, and Safety Outcomes for Young Children at Risk of or in Out-of-home Placement in Philadelphia and Bucks Counties, and Affected by Maternal Substance Use

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

A Randomized Trial of GM-CSF in Patients With ALI/ARDS

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

Study of Abemaciclib in Dedifferentiated Liposarcoma

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Development of an Empowerment Intervention for Young Women Living With HIV

A Pilot Study of Biomarkers for Spinal Muscular Atrophy

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

Prosperando: Fostering Resilience on Dialysis